Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Net Cash Flow: 2020-2024

Historic Net Cash Flow for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $438.1 million.

  • NewAmsterdam Pharma Co N.V's Net Cash Flow fell 94.67% to -$24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.1 million, marking a year-over-year increase of 133.22%. This contributed to the annual value of $438.1 million for FY2024, which is 431.06% up from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Net Cash Flow stood at $438.1 million, which was up 431.06% from -$132.3 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Net Cash Flow ranged from a high of $438.1 million in FY2024 and a low of -$132.3 million during FY2023.
  • Moreover, its 3-year median value for Net Cash Flow was $402.3 million (2022), whereas its average is $236.0 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Net Cash Flow surged by 805.34% in 2021 and then crashed by 132.89% in 2023.
  • NewAmsterdam Pharma Co N.V's Net Cash Flow (Yearly) stood at $6.1 million in 2020, then soared by 805.34% to $55.2 million in 2021, then skyrocketed by 629.32% to $402.3 million in 2022, then crashed by 132.89% to -$132.3 million in 2023, then skyrocketed by 431.06% to $438.1 million in 2024.